Healthcare Winners and Losers From Obamacare Repeal
The potential repeal of the Affordable Care Act will hurt hospitals, but we think some wide-moat pharma and biotech companies should be able to withstand the turbulence.
The potential repeal of the Affordable Care Act will hurt hospitals, but we think some wide-moat pharma and biotech companies should be able to withstand the turbulence.
Debbie Wang: With the Trump administration and Republican control of Congress, we think they are going to make an early attempt at dismantling key pieces of the Affordable Care Act. This will end up translating into more people being uninsured. We see this as a negative for hospitals because they will have more patients coming in who are uninsured, and that will drive up bad debt expense. We see this as a positive for pharma and biotech because they will no longer have to pay in the ACA-required fees which were used to help subsidize premiums for the lower-income insureds. And we see this as a mixed bag for managed care companies, in that they will now be able to pull out of the insurance exchanges that are not profitable, but on the other hand, they will probably still be required to write insurance for insureds who come in with a pre-existing condition.
For investors, we continue to look for companies in healthcare that have moats. So, companies like Johnson & Johnson or Pfizer or Medtronic that have wide economic moats are the ones that we think are most likely to be able to withstand the turbulence that we will probably be seeing in the near term.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.